Instalab

House Dust (Greer) IgE Test

See whether household dust is the hidden trigger behind your stuffy nose, itchy eyes, eczema, or wheezing.

Who benefits from House Dust (Greer) IgE testing

Sneezing or Congested Year-Round
This test can identify dust mites as the trigger behind perennial allergic rhinitis when symptoms never seem to follow a pollen season.
Living With Asthma That Won't Settle
If asthma flares indoors, in bed, or while cleaning, dust mite sensitization may be the trigger your management plan is missing.
Battling Stubborn Eczema
Dust mite IgE can identify a specific environmental driver behind atopic dermatitis flares that don't respond to skin care alone.
A Parent of an Allergy-Prone Child
Early dust mite sensitization predicts asthma and rhinitis later in childhood, and identifying it early opens the door to treatment.

About House Dust (Greer) IgE

If you wake up congested, sneeze through the morning, or notice your skin and breathing get worse indoors, the dust in your home may be doing more than you think. The proteins in house dust, particularly from microscopic dust mites that live in bedding, carpets, and upholstered furniture, are among the most common indoor triggers of allergic disease worldwide.

This test measures whether your immune system has produced antibodies against those dust proteins. A positive result points to a specific, treatable trigger behind allergic rhinitis, asthma, atopic dermatitis, and allergic eye disease, and it changes what you can actually do about your symptoms.

What This Test Actually Measures

The analyte is IgE (immunoglobulin E), a class of antibody made by your immune system's B cells after they encounter and react to an outside protein. The Greer house dust extract used on the test surface contains a complex mix of proteins from house dust, with house dust mite proteins being the dominant allergens. When your blood is exposed to that extract, the assay measures how much IgE in your sample binds to it.

A positive result means your immune system has been trained to recognize something in house dust as a threat. That sensitization is the biological starting point for the allergic reactions you feel as runny nose, itchy eyes, wheezing, or eczema flares. Importantly, sensitization on a blood test is not the same as guaranteed clinical allergy, a distinction we will come back to.

Allergic Rhinitis and Conjunctivitis

House dust mite IgE is one of the strongest indoor triggers of perennial allergic rhinitis, the year-round version of hay fever. In a Japanese study of 17,974 elementary school children, 18.8% had allergic rhinitis caused by house dust mites, a meaningful share of childhood symptoms that often gets dismissed as a permanent cold.

In children with allergic conjunctivitis, higher house dust mite IgE levels were linked to a higher likelihood of having other allergic diseases at the same time, including rhinitis, asthma, and eczema. A study of 2,972 children found that the higher the dust mite IgE, the more comorbid allergic conditions were present, meaning a high level is a signal that the immune response has spread across multiple tissues.

Asthma Risk

Children with house dust mite allergy and asthma show a wider range of IgE responses to mite proteins and higher overall levels than allergic children without asthma. In a study of 211 children, the asthmatic group recognized more individual mite proteins and had higher concentrations of IgE against them, suggesting that the breadth and intensity of sensitization track with respiratory disease severity.

Long-term exposure data backs this up. In a prospective study of 67 children followed from infancy, those exposed to higher levels of house dust mite allergen in early life were more likely to develop asthma later in childhood, with wheeze starting earlier in life. Higher mite IgE is not a passive observation, it tracks a process that shapes lung health over years.

Atopic Dermatitis

In people with eczema, IgE to certain dust mite proteins is linked to more severe skin disease. A study of 384 atopic patients found that sensitization to specific mite components (Der p 5, 20, and 21) was associated with both allergic asthma and atopic dermatitis, and incorporating these into testing improved how well clinicians could assess severity.

In infants under two years old, early house dust mite sensitization was associated with higher rates of atopic dermatitis and food allergies in a study of 1,793 children. For parents trying to understand why a baby's skin keeps flaring, a positive dust IgE can identify a specific trigger that environmental measures and treatment can target.

Why a Positive Result Is Not the Whole Story

A positive house dust IgE means you are sensitized. It does not automatically mean your symptoms are caused by dust. Among people who tested positive on both blood IgE and skin prick testing, only about 69 to 70% had their dust mite allergy confirmed by a nasal provocation test, the most direct check for whether exposure actually reproduces symptoms.

This is why a positive result is best read alongside your symptom pattern. If your nose runs when you change the sheets, if you wake up congested, if your asthma worsens in dusty rooms, a positive test moves dust mites from suspicion to high-confidence trigger. If you have no symptoms, a positive test still tells you something important: your immune system is primed, and clinical allergy can develop later, especially in children.

Reference Ranges

These cutoffs come from a study of 16,209 adults and children with allergic rhinitis in Korea using the ImmunoCAP assay, validated against skin prick test results. They are illustrative orientation, not a target. Your lab will likely report different numbers, and the optimal threshold for calling a result positive varies by age and by which mite species is measured.

TierRange (kU/L)What It Suggests
NegativeBelow 0.35No detectable IgE sensitization to house dust
Low positive0.35 to 0.70Sensitization present, clinical relevance often uncertain
Clinically suggestiveAbove 0.69 to 1.16Levels above this threshold more reliably correspond to a positive skin prick test and clinical dust mite allergy

Compare your results within the same lab over time for the most meaningful trend. The 0.35 kU/L cutoff is the traditional positivity threshold, but research shows it can both miss clinically relevant sensitization and label some sensitized people as having significant allergy when they may not.

Tracking Your Trend

A single dust IgE reading tells you whether you are sensitized today. The more useful information comes from how that number moves over months and years, especially if you are doing something about it. Allergen immunotherapy (the standard medical treatment for dust mite allergy) shifts antibody levels in characteristic ways: dust mite IgE often rises in the first months of treatment before slowly falling, and the pattern of change predicts who will respond best.

For most people, a sensible cadence is to get a baseline, retest 6 to 12 months after starting any allergen-targeted treatment or major environmental change, and then check annually if you are actively managing dust mite allergy. If you are stable and asymptomatic, less frequent testing is reasonable, but a once-and-done result misses the trajectory that actually matters.

When Results Can Be Misleading

A few situations can distort how a single reading should be interpreted:

  • Local versus blood allergy: some people have dust mite IgE in their nose and airway tissue but normal levels in the blood, a condition called local allergic rhinitis. A negative blood test does not rule it out if your symptoms strongly suggest dust mite allergy.
  • Sensitization without symptoms: a positive test alone does not confirm clinical allergy. Up to 30% of people with positive blood IgE and skin tests do not react when directly exposed to dust mite extract in the nose.
  • Extract limitations: the house dust extract on the test surface contains a mix of proteins, but it does not capture every individual mite allergen. People sensitized only to less common mite components can sometimes test negative on the standard extract.
  • Cross-reactivity with other species: IgE to dust mites can cross-react with proteins in shellfish and snails, so a positive dust test in someone who also reacts to seafood may reflect a related immune response rather than two separate allergies.

What to Do With an Abnormal Result

If your dust IgE is positive and your symptoms fit, the immediate next steps fall into three categories. First, confirm the clinical picture with an allergist if you are considering immunotherapy, since blood testing alone is not enough to commit to a multi-year treatment. Skin prick testing or nasal provocation can sharpen the diagnosis. Second, reduce exposure where it counts most, which is your bedroom. Mite-impermeable mattress and pillow encasings have the strongest evidence for reducing emergency hospital attendance for childhood asthma exacerbations.

Third, consider whether the broader allergic picture warrants further workup. A high dust IgE often comes with sensitization to other indoor allergens (pets, mold, cockroach), and a fuller environmental panel may be worth ordering. If you have asthma symptoms alongside dust sensitization, lung function testing and an asthma management plan with an allergist or pulmonologist is the next step. The goal is not just to know you are allergic, but to act on it.

What Moves This Biomarker

Evidence-backed interventions that affect your House Dust (Greer) IgE level

Up & Down
Subcutaneous allergen immunotherapy with house dust mite extract
This is the standard medical treatment for confirmed dust mite allergy. Dust mite IgE typically rises in the first months of treatment, then slowly declines over months to years, while symptom severity and medication use fall. In a real-world study of 3,568 patients, subcutaneous immunotherapy significantly improved long-term control of rhinitis and asthma and reduced new asthma development after at least 2 years of treatment. A retrospective study of 304 patients with allergic rhinitis found that 3 years of immunotherapy was a significant predictor of clinical remission.
MedicationStrong Evidence
Up & Down
Sublingual allergen immunotherapy tablet for house dust mite
A daily tablet that dissolves under the tongue alters the antibody response to dust mites over time. In a randomized trial of 834 adults with house dust mite allergic asthma, the tablet significantly reduced the risk of moderate or severe asthma exacerbations during inhaled steroid reduction. In a randomized trial of 1,460 children aged 5 to 11, the tablet effectively reduced house dust mite allergic rhinitis symptoms. Specific IgE shifts are accompanied by rising protective IgG4 antibodies.
MedicationStrong Evidence
Decrease
Dupilumab (anti-IL-4/IL-13 biologic) for severe atopic dermatitis
In adults with severe atopic dermatitis driven by type-2 inflammation, 52 weeks of dupilumab treatment significantly reduced blood levels of total IgE and allergen-specific IgE to house dust and storage mite allergens. If you have severe eczema with high dust mite IgE and you start this medication, expect the number to drop meaningfully as the underlying immune signaling is dialed down.
MedicationStrong Evidence
Increase
Early-life exposure to high concentrations of house dust mite allergen
In a prospective study of 67 children followed from infancy, exposure to higher levels of house dust mite allergen in the home during early childhood increased the likelihood of developing dust mite IgE, asthma, and earlier-onset wheeze. The home environment a child grows up in shapes how their immune system learns to recognize dust mite proteins.
LifestyleStrong Evidence
Decrease
Omalizumab (anti-IgE biologic) combined with house dust mite immunotherapy
This injectable biologic binds and neutralizes free IgE, lowering measurable IgE levels and reducing allergic symptoms. In a randomized trial of 334 children with asthma, omalizumab reduced asthma exacerbations and the need for inhaled corticosteroids. In case reports of patients with steroid-dependent allergic rhinitis and asthma, combining omalizumab with dust mite immunotherapy improved asthma control and reduced oral corticosteroid dependence.
MedicationModerate Evidence
Decrease
Move to high-altitude environment
Dust mites do not survive well at high altitude, where the air is drier and cooler. In a study of 218 asthmatic children, moving to high altitude reduced both the number of house dust mites in the environment and IgE levels in sensitized children. This is rarely a practical intervention but illustrates that sustained exposure reduction can change the antibody response itself.
LifestyleModerate Evidence
Decrease
Mite-impermeable mattress and pillow encasings for sensitized children
Allergen-impermeable bed encasings reduce direct exposure to mite proteins during sleep, which is when exposure is highest. A systematic review found that in children, this measure reduced emergency hospital attendance for asthma exacerbations, even though broader avoidance strategies have shown inconsistent effects on antibody levels and overall asthma control. The biological logic is that reduced sustained exposure slowly dampens the immune response.
LifestyleModest Evidence

Frequently Asked Questions

References

24 studies
  1. Posa D, Perna S, Resch Y, Lupinek C, Panetta V, Hofmaier S, Rohrbach a, Hatzler L, Grabenhenrich L, Tsilochristou O, Chen KW, Bauer C, Hoffman U, Forster J, Zepp F, Schuster a, Wahn U, Keil T, Lau S, Vrtala S, Valenta R, Matricardi PThe Journal of Allergy and Clinical Immunology2017
  2. Muddaluru V, Valenta R, Vrtala S, Schlederer T, Hindley J, Hickey PLC, Larché M, Tonti EAllergy2021
  3. Yang Y, Ma D, Huang N, Li W, Jiang Q, Wang Y, Wang X, Yang L, Zhu RItalian Journal of Pediatrics2021
  4. Walsemann T, Böttger M, Traidl S, Schwager C, Gülşen a, Freimooser S, Rösner L, Werfel T, Jappe UAllergy2022
  5. Resch Y, Michel S, Kabesch M, Lupinek C, Valenta R, Vrtala SThe Journal of Allergy and Clinical Immunology2015